Blueprint Medicines (BPMC)

Trade BPMC now with
6/3/2020 8:07:24 AM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5/29/2020 8:12:49 AM Blueprint Medicines Announces Data From Ongoing ARROW Clinical Trial Of Pralsetinib
5/15/2020 8:04:25 AM Blueprint Medicines Gets CRL From FDA For Avapritinib New Drug Application For Fourth-Line GIST
4/28/2020 7:16:13 AM Blueprint Medicines Says Phase 3 VOYAGER Trial Did Not Meet Primary Endpoint
3/16/2020 7:20:59 AM Blueprint Medicines : PIONEER Trial Shows Broad Activity Of Avapritinib Across Measures Of Mast Cell Burden
2/13/2020 8:13:27 AM Blueprint Medicines Q4 Loss Per Share $1.5 Vs Loss $1.83 Last Year
2/6/2020 8:18:33 AM Blueprint Medicines Announces PDUFA Date Extension For NDA Of Avapritinib By Three Months To May 14, 2020
1/22/2020 10:32:53 PM Blueprint Medicines Prices Underwritten Public Offering Of 4.71 Mln Shares $69.00/shr
1/8/2020 8:11:54 AM Blueprint Medicines Announces Top-line Data For Pralsetinib
1/6/2020 8:12:06 AM CStone, Blueprint Initiate Phase 1b/2 Trial Of Fisogatinib In Combination With CS1001 For Patients With HCC
11/5/2019 7:17:22 AM Blueprint Medicines Q3 Net Loss $94.3 Mln Or $1.93/shr Vs. Net Loss $72.7 Mln Or $1.66/shr Last Year
10/28/2019 8:09:40 AM Blueprint : FDA To Split Avapritinib NDA Into Separate Submissions For PDGFRA Exon 18 Mutant GIST And Fourth-Line GIST
8/7/2019 8:17:17 AM Blueprint Medicines Says FDA Accepts NDA For Avapritinib For PDGFRA Exon 18 Mutant GIST And Fourth-Line GIST